
|Articles|February 11, 2022
Reagan-Udall Foundation for the FDA Issues Paper on COVID-19 Lessons Learned: Clinical Evaluation of Therapeutics
Advertisement
The Reagan-Udall Foundation for the FDA, at the request of the US Food and Drug Administration, has released a report that outlines initial lessons learned from the federal government’s and research communities’ COVID-19 response and provides actionable recommendations to enhance the scope, prioritization, and communication of research activities within the context of a public health emergency. The report can be viewed
Additional information on the Reagan-Udall public workshop and Long-Term COVID can be found by following the links below:
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years
3
SCOPE X: The COPD Case Study That Shows What AI Can Do for Enrollment
4
Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention
5




